Labcorp Holdings Inc. (LH) has seen a busy period of activity recently. There has been an insider sell-off amounting to US$8.7m, and a price target increase by Morgan Stanley to $283. The company announced its Q1 2025 earnings, which showed growth in revenue but missed expectations. Mixed results also characterized Q4 2024, however, their overall stock has seen a rise of 25.6% this year. An investment in Labcorp five years ago would have yielded an 85% gain.
The company has made significant moves in expanding its services, including the acquisition of select assets of BioReference Health's oncology and testing businesses, developing a groundbreaking 1000+ biomarker platform, and launching Labcorp Whole Health Solutions. However, it is important to note that there was a miss on revenue estimates in Q1 2025, but the company still managed to raise their EPS guidance.
Labcorp’s stock price target was raised following strong Q1 results and it continues to score well as a value stock. There were several executive transactions recorded, with the notable retirement of CFO Glenn Eisenberg. The company also introduced FDA-approved self-collection tests for HPV and STIs, a 3D liver model project, and an Alzheimer's blood test showing 95% accuracy.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 23 Feb 2017 08:00:00 GMT to Wed, 02 Jul 2025 14:37:22 GMT - Rating 8 - Innovation 10 - Information 7 - Rumor -3
